Pharmacokinetics of Piperacillin and Meropenem in ICU Patients
Study Details
Study Description
Brief Summary
The purpose of the study is to characterize the pharmacokinetics of meropenem and piperacillin in ICU-patients at the time of the first dose administration and to contrast that with the same measurements obtained in the same patient 2-3 days later during the course of ICU treatment.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Study Kohort As specified by study population, inclusion and exclusion criteria |
Drug: Piperacillin/tazobactam, Meropenem
This is an observational study exploring the antibiotic plasma concentration profiles in ICU paitents after the first drug administration.
|
Outcome Measures
Primary Outcome Measures
- Volume of distribution [For the first antibiotic administration and if possible for a second administration 48-72 hour later.]
Apparent volume of distribution calculated from repeated plasma concentrations measurements and pharmacokinetic modelling.
- Plasma clearance [For the first antibiotic administration and if possible for a second administration 48-72 hour later.]
Plasma clearance calculated from repeated plasma concentrations measurements and pharmacokinetic modelling.
Secondary Outcome Measures
- Plasma antibiotic concentrations at mid and end of dosing interval [For the first antibiotic administration and if possible for a second administration 48-72 hour later.]
Plasma antibiotic concentrations at mid and end of dosing interval
Eligibility Criteria
Criteria
Inclusion Criteria:
- Patient being treated in one of the participating ICUs and planned to recieve treatment with meropenem or piperacillin.
Exclusion Criteria (fullfilling any exlusion criteria means that patient cannot be included in the study):
-
Not possible to retrospectively ask the patient or next of kin for consent to take part in the study or patient or next-of-kin not providing consent.
-
Not posisble to obtain and process blood samples as specified by protocol.
-
Ongoing renal replacement therapy.
-
Patient having received the same antibiotic within the previous 96 h.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Karolinska University Hospital | Stockholm | Sweden | 17176 |
Sponsors and Collaborators
- Karolinska University Hospital
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- K 2018-6443